United Therapeutics stock soars 9% on $2 billion buyback plan

LootboxPhobia · 2026-03-09T19:30:22+00:00

United Therapeutics announced a $2 billion stock buyback program, with the stock price rising by 9%. The plan includes a $1.5 billion accelerated share repurchase agreement, demonstrating management's confidence in business growth. This move comes after the release of positive research results for its drug ralinepag.

LootboxPhobia

2026-03-09 19:30:22

Abstract generation in progress

Investing.com – United Therapeutics Corporation (NASDAQ:UTHR) stock rose 9% on Monday after the company announced a new $2 billion share repurchase plan.

The Maryland-based biopharmaceutical company said its board of directors has authorized the repurchase plan, which includes an initial $1.5 billion accelerated share repurchase agreement with Citibank (NYSE:C). Up to an additional $500 million will be available for the company to repurchase at its discretion.

A week before this buyback announcement, United Therapeutics reported that its drug ralinepag reduced the risk of disease progression in a late-stage study for the treatment of a rare lung disease.

United Therapeutics sells several FDA-approved treatments for pulmonary arterial hypertension, including the oral drug Orenitram, the continuous infusion therapy Remodulin, and inhaler-based Tyvaso and Tyvaso DPI.

TD Cowen analyst comments, “UTHR announced that its board authorized a new share repurchase plan of up to $2 billion, including the $1.5 billion ASR plan executed today. We believe this indicates management’s confidence in the continued strong growth of the business, considering the drivers such as soft mist inhalers, ralinepag, and Tyvaso for IPF. We expect data from the Phase III TETON 1 study to be released in the coming weeks. Buy.”

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.